Justin Finch, MD
Dermatology · Cromwell, CTNPI 1437310869
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.4% of the total across 747 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 32 manufacturers, the largest accounting for just 22.7% — the pattern of someone who eats at a lot of different presentations.
Across 747 payments — averaging $20.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$3K
- Johnson & Johnson$2K
- Pfizer$1K
- Sanofi$884
- Lilly USA, LLC$849
- UCB, Inc.$707
- plus $6K from 26 others
What the payments were for
- Speaking & faculty fees$1101%
- Food & beverage$15,03397%
- Education$2922%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 192 | $3,498 |
| Johnson & Johnson | 89 | $1,970 |
| Pfizer | 62 | $1,254 |
| Sanofi | 36 | $884 |
| Lilly USA, LLC | 46 | $849 |
| UCB, Inc. | 38 | $707 |
| Regeneron Healthcare Solutions, Inc. | 24 | $691 |
| Novartis | 41 | $680 |
| Incyte Corporation | 26 | $665 |
| LEO Pharma Inc. | 35 | $654 |
| Sun Pharmaceutical Industries Inc. | 23 | $533 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 21 | $410 |
| Amgen | 18 | $403 |
| Arcutis Biotherapeutics, Inc. | 33 | $388 |
| E.r. Squibb & Sons, L.L.C. | 16 | $326 |
| Prugen, Inc. Pharmaceuticals | 1 | $276 |
| Galderma Laboratories, L.p. | 11 | $228 |
| Sanofi-aventis U.S. LLC | 2 | $176 |
| Dermira, Inc. | 7 | $143 |
| Almirall LLC | 7 | $115 |
| EPI Health, LLC | 1 | $110 |
| Aclaris Therapeutics, Inc. | 1 | $102 |
| Dermavant Sciences, Inc. | 5 | $102 |
| Janssen Scientific Affairs, LLC | 2 | $67 |
| Helsinn Therapeutics (U.S.), Inc. | 2 | $45 |
| Bristol Myers Squibb | 1 | $42 |
| VYNE Pharmaceuticals Inc. | 2 | $38 |
| Journey Medical Corporation | 1 | $20 |
| Organogenesis Inc. | 1 | $17 |
| Boehringer Ingelheim | 1 | $16 |
| Genentech USA, Inc. | 1 | $14 |
| Mayne Pharma Commercial LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$15,436 in reported general payments places this provider in the 80th percentile of 222 dermatology providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent PenDupilumab | 43 | $183,569 |
| ZoryveRoflumilast | 15 | $13,179 |
| Clobetasol Propionate | 86 | $2,492 |
| Mycophenolate Mofetil | 20 | $2,202 |
| Ketoconazole | 46 | $1,320 |
| Imiquimod | 27 | $1,104 |
| Metronidazole | 26 | $1,086 |
| Triamcinolone Acetonide | 124 | $1,057 |
| Tacrolimus | 17 | $867 |
| Fluorouracil | 13 | $685 |
| Clindamycin Phosphate | 17 | $407 |
| Minoxidil | 18 | $390 |
| Ammonium Lactate | 29 | $343 |
| Nystatin | 12 | $333 |
| Econazole Nitrate | 16 | $298 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Arcutis Biotherapeutics, Inc.Zoryve | $388 | $13,17915 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 222 dermatology providers in Connecticut.
Other dermatology in Cromwell
- Michael PayetteCromwell$3.2M
- Bruce StroberCromwell$2.9M
- Mona ShahriariCromwell$2.2M
- Mark MarchittoCromwell$249K
- Steven MadsenCromwell$11K
- Brett KingFairfield$2.5M
- Jeremy MossMadison$2M
- Brittany CraiglowFairfield$1.9M
- Meagen McCuskerEnfield$1.8M
- Marcus McFerrenOrange$872K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.